Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 3:14:1-10.
doi: 10.2147/CEOR.S327191. eCollection 2022.

Cost-Effectiveness Analysis for the Treatment of Diabetic Foot Ulcer in France: Platelet-Rich Plasma vs Standard of Care

Salvatore Russo #  1 , Stefano Landi #  2 , Stephane Courric  3
Affiliations

Cost-Effectiveness Analysis for the Treatment of Diabetic Foot Ulcer in France: Platelet-Rich Plasma vs Standard of Care

Salvatore Russo et al. Clinicoecon Outcomes Res. .

Abstract

Introduction: Diabetic chronic foot ulcers (DFU) lead to pain, reduced quality of life and represent a severe economic burden for patients and health systems. The clinical results of PRP effectiveness in the treatment of DFU are promising; on the other hand, the costs associated with treating DFUs with PRP are higher than those using standard therapy. Therefore, this study aims to determine the cost-effectiveness of platelet-rich plasma (PRP) therapy compared to standard therapy from the French healthcare system perspective.

Methods: A cost-effectiveness analysis (CEA) was performed using a decision Markov model with a cohort of patients with chronic DFU (duration of >3 weeks) with high orthopaedic risk and with ulcers graded 3A according to University of Texas classification. The effectiveness outcomes are reported in terms of quality adjusted life year (QALY). The costs are reported in euro (€) currency evaluated in 2019. A micro-costing approach alongside a clinical study was used to assess resource use. Deterministic sensibility analyses are reported to evaluate the robustness of the results. The analyses were carried out in the French setting.

Results: The incremental cost-effectiveness ratio (ICER) of PRP treatment is -€613/ QALY, which, being lower than zero, indicates the dominance of the PRP therapy. Deterministic and probabilistic sensitivity analysis underlines the main parameter affecting CE results. Lowest number of standard of care weekly medications (from 5 to 3) leads to a €622/QALY while increasing PRP weekly medication (from 1 to 4) has an ICER of €732/QALY.

Discussion: PRP is a cost-effective or even a cost-saving alternative in the French setting. PRP has higher cost for the complete medication, but, in the absence of wound complications, has the potential to involve lower consumption of resources in the form of routine medication over a 1-year time horizon.

Keywords: cost-effectiveness analysis; cost-utility analysis; diabetic foot ulcer; platelet-rich plasma.

PubMed Disclaimer

Conflict of interest statement

SC formerly worked for Regen Lab as external consultant. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Markov model of diabetic foot ulcer. States are identical for usual and PRP care.
Figure 2
Figure 2
Tornado analysis.
Figure 3
Figure 3
Cumulative cost per week of the two therapies.
Figure 4
Figure 4
Cost-effectiveness acceptability curve of PRP vs SoC under various WTP thresholds.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rayner R, Carville K, Keaton J, et al. Leg ulcers: atypical presentations and associated co-morbidities. Wound Pract Res. 2009;17(4):168–185.
    1. Agale SV. Chronic leg ulcers: epidemiology, aetiopathogenesis, and management. Ulcers. 2013;Article ID 413604:9.
    1. Greer N, Foman N, Dorrian J, et al. Advanced wound care therapies for nonhealing diabetic, venous, and arterial ulcers: a systematic review. VAESP Project #09-009; 2012. - PubMed
    1. Abbott CA, Carrington AL, Ashe H, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community – based patient cohort. Diabet Med. 2002;19:377–384. doi:10.1046/j.1464-5491.2002.00698.x - DOI - PubMed
    1. Abbott CA, Vileikyte L, Williamson S, et al. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care. 1998;21:1071. doi:10.2337/diacare.21.7.1071 - DOI - PubMed